Patents Assigned to Myraid Genetics, Inc.
  • Protein-protein interactions
    Publication number: 20020164666
    Abstract: The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: December 20, 2001
    Publication date: November 7, 2002
    Applicant: MYRAID GENETICS, INC.
    Inventors: Daniel M. Cimbora, Karen Heichman, Paul L. Bartel
  • MMSC1-an MMAC1 interacting protein
    Patent number: 6337192
    Abstract: The present invention is directed to the MMSC1 gene, its protein product and the use of the protein to (i) detect mutant MMAC1 proteins, (ii) screen for drugs which can be used for suppressing tumor growth and (iii) identify proteins which interact with the MMAC1 gene or are involved in the tumor suppression pathway of the MMAC1 gene.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: January 8, 2002
    Assignee: Myraid Genetics, Inc.
    Inventors: Paul L. Bartel, Sean V. Tavtigian
  • 17Q-linked breast and ovarian cancer susceptibility gene
    Patent number: 5747282
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 5, 1998
    Assignees: Myraid Genetics, Inc., University of Utah Research Foundation, The United States of America as represented by the Secretary of Health and Human Services
    Inventors: Mark H. Skolnick, David E. Goldgar, Yoshio Miki, Jeff Swenson, Alexander Kamb, Keith D. Harshman, Donna M. Shattuck-Eidens, Sean V. Tavtigian, Roger W. Wiseman, P. Andrew Futreal